Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$43.39 - $51.63 $22,519 - $26,795
519 New
519 $26,000
Q1 2023

May 17, 2023

SELL
$33.58 - $41.2 $3,257 - $3,996
-97 Reduced 15.75%
519 $18,000
Q4 2022

Feb 13, 2023

BUY
$37.12 - $46.52 $22,865 - $28,656
616 New
616 $23,000
Q3 2021

Nov 05, 2021

SELL
$33.54 - $40.55 $17,407 - $21,045
-519 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$34.54 - $47.25 $17,926 - $24,522
519 New
519 $21,000
Q1 2021

May 24, 2021

SELL
$42.51 - $63.78 $49,694 - $74,558
-1,169 Closed
0 $0
Q4 2020

Feb 09, 2021

BUY
$45.3 - $60.27 $26,953 - $35,860
595 Added 103.66%
1,169 $66,000
Q3 2020

Nov 16, 2020

BUY
$47.45 - $62.95 $27,236 - $36,133
574 New
574 $28,000
Q2 2020

Aug 10, 2020

SELL
$46.85 - $61.05 $242,823 - $316,422
-5,183 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$41.6 - $63.4 $108,451 - $165,283
-2,607 Reduced 33.47%
5,183 $245,000
Q4 2019

Feb 04, 2020

BUY
$53.85 - $65.27 $370,649 - $449,253
6,883 Added 758.88%
7,790 $471,000
Q2 2019

Aug 01, 2019

BUY
$62.09 - $86.14 $15,646 - $21,707
252 Added 38.47%
907 $0
Q1 2019

May 20, 2019

SELL
$52.92 - $81.17 $5,397 - $8,279
-102 Reduced 13.47%
655 $53,000
Q4 2018

Feb 15, 2019

BUY
$43.37 - $59.54 $6,722 - $9,228
155 Added 25.75%
757 $41,000
Q2 2018

Jul 27, 2018

SELL
$40.53 - $50.7 $43,691 - $54,654
-1,078 Reduced 64.17%
602 $28,000
Q1 2018

Apr 23, 2018

SELL
$44.08 - $55.05 $10,931 - $13,652
-248 Reduced 12.86%
1,680 $0
Q4 2017

Feb 08, 2018

SELL
$50.3 - $64.39 $67,603 - $86,540
-1,344 Reduced 41.08%
1,928 $97,000
Q3 2017

Oct 12, 2017

BUY
$45.56 - $59.57 $121,645 - $159,051
2,670 Added 443.52%
3,272 $166,000
Q2 2017

Aug 17, 2017

BUY
N/A
602
602 $31,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $4.73B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Advisory Services Network, LLC Portfolio

Follow Advisory Services Network, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Advisory Services Network, LLC with notifications on news.